Molecular Formula | C33H31F3N6O2 |
Molar Mass | 600.63 |
Solubility | Soluble in DMSO |
Storage Condition | -20℃ |
Use | The MRTX1133 of use is selective and reversible KRAS-G12D inhibitors, which can inhibit KRAS G12D mutant cells in activated and inactivated state, but not KRAS wild-type tumor cells, MRTX1133 the specificity of KRAS G12D is more than 1000 times that of wild-type KRAS. |
Reference Show more | 1. Wang X, et al. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor [published online ahead of print, 2021 Dec 10]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01688.2. KRAS G12D Inhibitor: MRTX1133. [(accessed on 22 April 2021)];2021 Available online. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.665 ml | 8.324 ml | 16.649 ml |
5 mM | 0.333 ml | 1.665 ml | 3.33 ml |
10 mM | 0.166 ml | 0.832 ml | 1.665 ml |
5 mM | 0.033 ml | 0.166 ml | 0.333 ml |
use | MRTX1133 is a selective and reversible KRAS-G12D inhibitor, which can inhibit KRAS G12D mutant cells in activated and inactivated state, but does not inhibit KRAS wild-type tumor cells. the specificity of MRTX1133 for KRAS G12D is more than 1000 times that of wild-type KRAS. |